ALK-Abelló Past Earnings Performance
Past criteria checks 4/6
ALK-Abelló has been growing earnings at an average annual rate of 42.9%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 11.6% per year. ALK-Abelló's return on equity is 19.5%, and it has net margins of 19.5%.
Key information
42.86%
Earnings growth rate
42.71%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.39% |
| Revenue growth rate | 11.62% |
| Return on equity | 19.49% |
| Net Margin | 19.51% |
| Next Earnings Update | 20 Aug 2026 |
Recent past performance updates
Recent updates
Narrative Update • Apr 24
ALK B: Future Upside Will Come From Needle Free Anaphylaxis Treatment Adoption
Analysts have nudged their price target for ALK-Abelló to DKK 263.33 from DKK 255, reflecting updated assumptions around slightly adjusted revenue growth, profit margin expectations, and a higher future P/E multiple. What's in the News ALK reported positive topline phase 2 data from the ALLIANCE trial of its once daily sublingual immunotherapy tablet for peanut allergy in patients aged 4 to 65 years, with statistically significant, dose dependent efficacy across multiple tolerated dose and eliciting dose endpoints and a safety profile without treatment related anaphylaxis or serious adverse events (Key Developments).Narrative Update • Apr 09
ALK B: Future Upside Will Come From Wider Needle Free Anaphylaxis Treatment Adoption
Analysts have adjusted their DKK price targets for ALK-Abelló to reflect updated assumptions for revenue growth of 13.31%, profit margin of 20.66% and a future P/E of 34.79. This suggests a modest recalibration in how the company’s earnings power is being valued.Narrative Update • Mar 25
ALK B: Future Upside Will Rely On Wider Anaphylaxis Spray Adoption
Analysts have kept their DKK price target for ALK-Abelló broadly unchanged at DKK 255, reflecting stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E. This signals a steady view on the company’s outlook.Narrative Update • Mar 11
ALK B: Future Upside Will Rely On Wider Anaphylaxis Treatment Adoption
Analysts have kept their DKK 255.00 price target for ALK-Abelló unchanged, indicating that their views on fair value, discount rate, expected revenue growth, profit margin and future P/E assumptions remain broadly steady. What's in the News ALK-Abelló presented late-breaking data from a 90-participant study comparing needle-free EURneffy nasal adrenaline to injectable auto-injectors for anaphylaxis, with 88% of participants preferring EURneffy, mainly for ease of use, portability and the absence of a needle (AAAAI 2026 Annual Meeting).Narrative Update • Feb 25
ALK B: Future Returns Will Rely On Expanded Anaphylaxis Indications And Stronger Margins
Analysts have nudged their price target on ALK-Abelló up from DKK 249 to DKK 255, reflecting updated assumptions that combine slightly lower expected revenue growth with a higher projected profit margin and a modestly lower future P/E multiple. What's in the News ALK Abelló issued earnings guidance for 2026, indicating an expectation of continued double digit revenue growth and higher earnings, with revenue projected to grow 11 to 15% in local currencies (company guidance).Narrative Update • Feb 10
ALK B: Future Returns Will Rely On Expanded Anaphylaxis Reach And Higher 2025 Margins
Analysts have lifted their fair value estimate for ALK-Abelló from DKK 214 to DKK 249, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion recommending EU marketing authorisation for EURneffy 1 mg nasal adrenaline spray for emergency treatment of anaphylaxis in children aged 4 years and older weighing 15 kg to 30 kg.Narrative Update • Jan 27
ALK B: Future Returns Will Reflect Upgraded 2025 Outlook And Stable Margin Ambitions
Analysts have kept their price target for ALK-Abelló steady at DKK 214. This reflects unchanged assumptions around discount rate, revenue growth, profit margin and future P/E, and indicates that new research has not materially shifted their valuation view.
New Narrative • Jan 23
Pediatric Allergy Tablets And Food Programs Will Drive A Long Runway Of Opportunity
Catalysts About ALK-Abelló ALK Abelló develops and commercialises allergy immunotherapy tablets, injectable and drop therapies, along with anaphylaxis treatments such as Jext and neffy. What are the underlying business or industry changes driving this perspective?Analysis Article • Jan 23
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Narrative Update • Jan 12
ALK B: Future Returns Will Reflect Upgraded Outlook And Balanced Margin Prospects
Analysts have trimmed their price target for ALK-Abelló to €214.00 from €219.33, citing updated assumptions that now reflect slightly higher revenue growth, a modestly lower profit margin outlook and a small adjustment to the projected future P/E multiple. What's in the News ALK-Abelló upgraded its earnings guidance for the full year 2025, with expected revenue growth of 13% to 15% in local currencies, compared with a previous range of 12% to 14% (Key Developments).Narrative Update • Dec 19
ALK B: Future Returns Will Reflect Upgraded Outlook And Solid Margin Prospects
Analysts have modestly lifted their average price target on ALK-Abelló to DKK 219.33, reflecting steady confidence in the company’s unchanged long term growth, margin, and valuation assumptions despite minimal adjustments to underlying model inputs. What's in the News Upgraded 2025 revenue guidance to 13% to 15% growth in local currencies, from 12% to 14%, supported by stronger demand across all regions and product lines (company guidance).Analysis Article • Dec 08
Investors Appear Satisfied With ALK-Abelló A/S' (CPH:ALK B) Prospects
With a price-to-earnings (or "P/E") ratio of 45.8x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...Narrative Update • Dec 05
ALK B: Future Returns Will Reflect China Alliance And Margin Outlook
Analysts have maintained their DKK 219.33 price target for ALK Abelló, reflecting stable expectations for sustained double digit revenue growth, robust profit margins and a premium future P E multiple. What's in the News Upgraded 2025 guidance, with expected revenue growth raised to 13% to 15% in local currencies, supported by higher treatment volumes across allergy immunotherapy and anaphylaxis products, and an improved projected EBIT margin of about 26% (company guidance).Narrative Update • Nov 21
ALK B: Improved Margins and China Partnership Will Drive Steady Outlook
Analysts have raised their price target for ALK-Abelló to DKK 219.33 from DKK 196.00. They cite ongoing improvements in profit margins and a slightly higher projected fair value as the reasons for the adjustment.Analysis Article • Nov 15
ALK-Abelló A/S (CPH:ALK B) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a pretty great week for ALK-Abelló A/S ( CPH:ALK B ) shareholders, with its shares surging 15% to kr.230 in...Narrative Update • Nov 04
ALK B: Chinese Partnership And Revenue Upside Will Drive Future Opportunities
Analysts have raised their price target for ALK-Abelló from DKK 193 to DKK 196. This change is based on slightly improved revenue growth estimates and valuation adjustments.Analysis Article • Oct 11
Does ALK-Abelló (CPH:ALK B) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Aug 23
Allergy+ Strategy Will Reach Millions With New Therapies
The increase in ALK-Abelló’s analyst price target is primarily driven by a modest upward revision in consensus revenue growth forecasts, while net profit margins remain steady, resulting in a new fair value estimate of DKK192.33 per share. What's in the News ALK-Abelló raised its 2025 revenue growth guidance to 12-14% (from 9-13%) in local currencies, supported by strong adrenaline autoinjector and tablet sales in Europe and North America, and will allocate additional funds to strategic growth investments.Analysis Article • Jul 23
ALK-Abelló A/S' (CPH:ALK B) Popularity With Investors Is Clear
With a price-to-earnings (or "P/E") ratio of 44.9x ALK-Abelló A/S ( CPH:ALK B ) may be sending very bearish signals at...Analysis Article • Jun 17
ALK-Abelló (CPH:ALK B) Seems To Use Debt Quite Sensibly
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Narrative • Dec 11
Allergy+ Strategy And Neffy Nasal Spray Will Ignite Revenue Growth And Boost Earnings
The Allergy+ strategy and neffy nasal spray deal are expected to create new revenue streams and drive growth from 2025 onward.Revenue & Expenses Breakdown
Revenue & Expenses Breakdown
How ALK-Abelló makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 6,561 | 1,280 | 2,061 | 631 |
| 31 Dec 25 | 6,312 | 1,197 | 1,972 | 609 |
| 30 Sep 25 | 6,078 | 1,101 | 1,949 | 587 |
| 30 Jun 25 | 5,861 | 999 | 1,901 | 551 |
| 31 Mar 25 | 5,708 | 937 | 1,906 | 530 |
| 31 Dec 24 | 5,537 | 815 | 1,932 | 531 |
| 30 Sep 24 | 5,383 | 785 | 1,851 | 515 |
| 30 Jun 24 | 5,180 | 690 | 1,814 | 555 |
| 31 Mar 24 | 4,941 | 555 | 1,784 | 590 |
| 31 Dec 23 | 4,824 | 486 | 1,753 | 618 |
| 30 Sep 23 | 4,728 | 424 | 1,700 | 652 |
| 30 Jun 23 | 4,680 | 359 | 1,722 | 664 |
| 31 Mar 23 | 4,590 | 335 | 1,702 | 666 |
| 31 Dec 22 | 4,511 | 335 | 1,656 | 665 |
| 30 Sep 22 | 4,361 | 333 | 1,641 | 658 |
| 30 Jun 22 | 4,227 | 318 | 1,586 | 644 |
| 31 Mar 22 | 4,050 | 255 | 1,499 | 654 |
| 31 Dec 21 | 3,916 | 219 | 1,463 | 630 |
| 30 Sep 21 | 3,808 | 112 | 1,442 | 611 |
| 30 Jun 21 | 3,652 | 55 | 1,385 | 585 |
| 31 Mar 21 | 3,556 | 66 | 1,359 | 516 |
| 31 Dec 20 | 3,491 | 25 | 1,363 | 496 |
| 30 Sep 20 | 3,383 | 43 | 1,347 | 486 |
| 30 Jun 20 | 3,350 | 49 | 1,389 | 489 |
| 31 Mar 20 | 3,363 | -9 | 1,439 | 480 |
| 31 Dec 19 | 3,274 | -50 | 1,461 | 466 |
| 30 Sep 19 | 3,178 | -183 | 1,470 | 425 |
| 30 Jun 19 | 3,100 | -200 | 1,442 | 385 |
| 31 Mar 19 | 3,030 | -149 | 1,412 | 377 |
| 31 Dec 18 | 2,915 | -170 | 1,366 | 360 |
| 30 Sep 18 | 2,891 | -183 | 1,336 | 395 |
| 30 Jun 18 | 2,897 | -152 | 1,327 | 399 |
| 31 Mar 18 | 2,873 | -136 | 1,314 | 410 |
| 31 Dec 17 | 2,910 | -158 | 1,298 | 426 |
| 30 Sep 17 | 2,901 | 37 | 1,233 | 386 |
| 30 Jun 17 | 2,864 | 76 | 1,175 | 383 |
| 31 Mar 17 | 2,946 | 149 | 1,133 | 383 |
| 31 Dec 16 | 3,005 | 270 | 1,091 | 385 |
| 30 Sep 16 | 2,938 | 373 | 1,063 | 406 |
| 30 Jun 16 | 2,975 | 396 | 1,055 | 412 |
| 31 Mar 16 | 2,767 | 378 | 1,038 | 416 |
| 31 Dec 15 | 2,569 | 344 | 1,033 | 407 |
| 30 Sep 15 | 2,494 | 221 | 1,029 | 399 |
| 30 Jun 15 | 2,349 | 185 | 1,018 | 396 |
Quality Earnings: ALK B has high quality earnings.
Growing Profit Margin: ALK B's current net profit margins (19.5%) are higher than last year (16.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALK B's earnings have grown significantly by 42.9% per year over the past 5 years.
Accelerating Growth: ALK B's earnings growth over the past year (36.6%) is below its 5-year average (42.9% per year).
Earnings vs Industry: ALK B earnings growth over the past year (36.6%) exceeded the Pharmaceuticals industry 16.1%.
Return on Equity
High ROE: ALK B's Return on Equity (19.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 06:38 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ALK-Abelló A/S is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Jesper Ilsoe | Carnegie Investment Bank AB |
| Jesper Ingildsen | DNB Carnegie |